Cinepazide maleate NEW
Price | $33 | $50 | $65 |
Package | 10mg | 25mg | 50mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Cinepazide maleate | CAS No.: 26328-04-1 |
Purity: 99.9% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Cinepazide maleate |
Description | Cinepazide maleate (MD-67350), a maleate salt form of cinepazide, is a vasodilator. |
In vitro | Cinepazide exhibits strong chronotropic and inotropic effects. Intravenous administration of Cinepazide (1 mg/kg - 3 mg/kg) leads to an 8% increase in heart rate while reducing blood pressure by 4%. Cinepazide selectively enhances the functional activity of 5-HT neurons in the brain, although hypoxia inhibits its activity. Doses of Cinepazide (3 mg/kg - 30 mg/kg) administered intravenously transiently increase renal and femoral arterial blood flow, spinal and carotid blood flow, and cardiac output in anesthetized dogs while decreasing total peripheral resistance, exhibiting a concentration-dependent relationship with these effects. At 30 mg/kg, Cinepazide enhances the dilatory neural response of dog spinal blood vessels to intrathecal adenosine and adenylic acid. Cinepazide (1 mg - 10 mg) amplifies blood flow within spinal vessels in a dose-dependent manner, partially inhibited by pretreatment with intravenous aminophylline and unaffected by autonomic antagonists. Cinepazide is well absorbed, with over 60% excreted within 24 hours. Over five days, the excretion of Cinepazide through feces and urine is 58.3% and 36.7% in rats, 68.6% and 33.4% in dogs, and 38.1% and 61.3% in humans, respectively. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : 98 mg/mL (183.7 mM) DMSO : 99 mg/mL (185.5 mM) |
Keywords | Calcium Channel | stroke | Inhibitor | brain?infarct | Cinepazide Maleate | Ca2+ channels | Cinepazide | piperazine derivative | Ca channels | MD 67350 | vasodilator | Cinepazide maleate | cerebrovascular disease | ischemic | MD67350 | inhibit |
Inhibitors Related | Nisoldipine | Nimodipine | 2,5-Di-tert-butylhydroquinone | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Ethyl cinnamate | 1-Octanol | Otilonium bromide |
Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$33.00/10mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$320.00/1kg |
Hebei Mingeng Biotechnology Co., Ltd
|
2022-05-05 | ||
$0.00/1Kg/Bag |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-10-18 | |
$5.00/1KG |
Longyan Tianhua Biological Technology Co., Ltd
|
2020-10-27 | ||
$0.00/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-11 | |
$7.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-08-21 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY